세계의 바이오마커 탐색 아웃소싱 시장 : 산업 분석, 시장 규모, 점유율, 성장 동향, 예측(2025-2032년)

Biomarker Discovery Outsourcing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,838,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 9,987,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,630,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계 바이오마커 탐색 아웃소싱 서비스 시장에 대한 종합적인 보고서를 발표하여 추진력, 새로운 동향, 기회, 과제 등 주요 시장 역학에 대한 상세한 분석을 제공했습니다.

주요 인사이트

• 바이오마커 탐색 아웃소싱 서비스 시장 규모(2025년) : 148억 달러
• 시장 규모 예측(금액 기준, 2032년) : 384억 달러
• 세계 시장의 성장률(CAGR, 2025-2032년) : 14.5%

바이오마커 탐색 아웃소싱 서비스 시장 분석 범위

바이오마커 탐색 아웃소싱 서비스 시장은 의약품 개발 및 질병 진단에 사용되는 생물학적 마커를 확인하고 검증하기 위한 전문 서비스의 아웃소싱을 말합니다. 약품 개발의 복잡성이 늘어남에 따라 기업은 첨단 기술과 전문 지식을 이용하고 비용을 절감하고 일정을 단축하기 위해 개발 업무 수탁기관(CRO)과 외부 서비스 제공업체를 이용하게 되어 왔습니다.

시장 성장 촉진요인 :

시장 성장 촉진요인은 여러 가지가 있습니다. 암, 심혈관 질환, 신경 질환 등의 만성 질환이나 복잡한 질환의 유병률 증가에 의해 바이오마커 탐색에 크게 의존하는 정밀의료의 필요성이 높아지고 있습니다. 유전체학, 단백질체학, 바이오인포매틱스의 기술 진보에 의해 신규 바이오마커의 동정이 용이하게 되어, 시장 수요가 한층 더 증가하고 있습니다.

시장 성장 억제요인 :

견고한 성장이 예상되는 바이오마커 탐색 아웃소싱 서비스 시장은 여러 과제에 직면하고 있습니다. 데이터 보안 문제와 지적 재산권(IP) 위험도 특히 국경 간 협업에서 상당한 장벽을 제기합니다. 또한, 숙련된 전문가의 부족과 바이오마커 조사 기법의 표준화의 한계는 서비스의 질과 재현성에 영향을 미치고, 임상 결과에 영향을 미칠 가능성이 있습니다.

시장 기회 :

맞춤형 치료와 정밀 진단 수요가 세계적으로 높아지는 가운데, 이 시장에는 큰 비즈니스 기회가 존재합니다. 아시아 태평양 및 라틴 아메리카의 신흥 시장은 증가하는 환자 기반, 증가하는 의료 인프라, 비용 이점으로 인해 미개척 잠재력을 제공합니다. 바이오마커 분석에 있어서의 인공지능(AI)과 머신러닝(ML)의 통합은 탐색의 스피드와 정밀도를 높이고, 혁신의 새로운 길을 엽니다. CRO와 제약 기업의 전략적 제휴, 합병, 인수는 능력과 서비스 포트폴리오를 확장하여 시장 성장을 더욱 가속화할 수 있습니다.

이 보고서에서 답변을 얻을 수 있는 주요 질문

• 세계의 바이오마커 탐색 아웃소싱 서비스 시장의 성장을 가속하는 주요 요인은?
• 아웃소싱 서비스 수요가 가장 높은 치료 분야와 탐색 단계는?
• 유전체학와 AI의 기술진보는 시장 역학에 어떤 영향을 주고 있는가?
• 바이오마커 탐색 아웃소싱 서비스 시장의 주요 기업은 어느 것으로, 어떤 전략을 채용하고 있는가?
• 세계의 바이오마커 탐색 아웃소싱 서비스 시장의 새로운 동향과 예측은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 국제무역정책이 분석기기에 미치는 영향
  • 경제회복과 의료연구비 증가
• COVID-19의 영향 분석
• 예측 요인 : 관련성과 영향

제3장 부가가치 분석

• 바이오마커 유형 수요 분석
• 규제 상황
• 밸류체인 분석
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계 바이오마커 탐색 아웃소싱 서비스 시장 전망

• 주요 하이라이트
  • 시장 규모 예측(수량 기준)
  • 시장 규모와 전년대비 성장률(금액 기준(10억 달러))
  • 절대 수익 기회
• 시장 규모의 분석과 예측(금액 기준(10억 달러))
  • 과거 시장 규모 분석(금액 기준(10억 달러), 2019-2024년)
  • 현재 시장 규모의 분석과 예측(금액 기준(10억 달러), 2025-2032년)
• 세계의 바이오마커 탐색 아웃소싱 서비스 시장 전망 : 바이오마커유형별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 유형별(금액(10억 달러) 및 수량 기준, 2019-2024년)
  • 현재 시장 규모의 분석과 예측 : 유형별(금액(10억 달러) 및 수량 기준, 2025-2032년)
    • 예측 바이오마커
    • 예후 바이오마커
    • 안전성 바이오마커
    • 대체 바이오마커
  • 시장 매력 분석 : 바이오 마커유형별
• 세계 바이오마커 탐색 아웃소싱 서비스 시장 전망 : 치료영역별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 유형별(금액 기준(10억 달러), 2019-2024년)
  • 현재 시장 규모의 분석과 예측 : 유형별(금액 기준(10억 달러), 2025-2032년)
    • 종양
    • 심장병
    • 신경증
    • 자가면역질환
    • 기타
  • 시장 매력 분석 : 치료 영역별
• 세계의 바이오마커 탐색 아웃소싱 서비스 시장 전망 : 탐색 단계별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 탐색 단계별(금액 기준(10억 달러), 2019-2024년)
  • 현재 시장 규모의 분석과 예측 : 탐색 단계별(금액 기준(10억 달러), 2025-2032년)
    • 바이오마커의 동정
    • 바이오마커의 검증
    • 바이오마커프로파일링
    • 바이오마커 패널 개발
    • 바이오마커의 선택
  • 시장 매력 분석 : 탐색 단계별
• 세계 바이오마커 탐색 아웃소싱 서비스 시장 전망 : 최종 용도별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 최종 용도별(금액 기준(10억 달러), 2019-2024년)
  • 현재 시장 규모의 분석과 예측 : 최종 용도별(금액 기준(10억 달러), 2025-2032년)
    • 제약회사
    • 바이오테크놀러지 기업
    • 기타
  • 시장 매력 분석 : 최종 용도별

제5장 세계의 바이오마커 탐색 아웃소싱 서비스 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모 분석 : 지역별(금액(10억 달러)·수량 기준, 2019-2024년)
• 현재 시장 규모의 분석과 예측 : 지역별(금액(10억 달러)·수량 기준, 2025-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제6장 북미 바이오마커 탐색 아웃소싱 서비스 시장 전망

제7장 유럽 바이오마커 탐색 아웃소싱 서비스 시장 전망

제8장 동아시아 바이오마커 탐색 아웃소싱 서비스 시장 전망

제9장 남아시아 오세아니아의 바이오마커 탐색 아웃소싱 서비스 시장 전망

제10장 라틴아메리카 바이오마커 탐색 아웃소싱 서비스 시장 전망

제11장 중동 및 아프리카 바이오마커 탐색 아웃소싱 서비스 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 프로파일(상세: 개요, 재무, 전략, 최근 동향)
  • Laboratory Corporation of America Holdings
  • Celerion
  • Charles River Laboratories
  • Eurofins Scientific
  • GHO Capital
  • ICON plc
  • Evotec
  • Parexel International(MA) Corporation
  • Thermo Fisher Scientific Inc.
  • Proteome Sciences
  • Others

제13장 부록

• 분석 방법
• 분석의 전제조건
• 두자어 및 약어

SHW

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Biomarker Discovery Outsourcing Services Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Biomarker Discovery Outsourcing Services Market Size (2025E): US$ 14.8 Bn
• Projected Market Value (2032F): US$ 38.4 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 14.5%

Biomarker Discovery Outsourcing Services Market - Report Scope:

The biomarker discovery outsourcing services market refers to the outsourcing of specialized services to identify and validate biological markers used in drug development and disease diagnosis. This includes services related to biomarker identification, validation, profiling, and selection, often utilized by pharmaceutical and biotechnology companies. As the complexity of drug development increases, companies are increasingly turning to contract research organizations (CROs) and external service providers to access advanced technologies and expertise, reduce costs, and accelerate timelines. The rising demand for personalized medicine, the surge in chronic diseases, and the need for efficient clinical trials are accelerating the growth of this market.

Market Growth Drivers:

The market is witnessing significant growth due to several key drivers. The increasing prevalence of chronic and complex diseases such as cancer, cardiovascular, and neurological disorders has heightened the need for precision medicine, which relies heavily on biomarker discovery. Pharmaceutical and biotechnology companies are under pressure to enhance drug development efficiency, pushing them to outsource complex biomarker research to reduce time and cost. Technological advancements in genomics, proteomics, and bioinformatics have made it easier to identify novel biomarkers, further stimulating market demand. Additionally, the regulatory support for biomarker-based clinical trials and drug approvals is encouraging investment in outsourced biomarker discovery services.

Market Restraints:

Despite robust growth prospects, the biomarker discovery outsourcing services market faces several challenges. High service costs and the complexity of biomarker validation processes can deter small and mid-sized enterprises from outsourcing. Data security concerns and intellectual property (IP) risks also pose significant barriers, especially in cross-border collaborations. Moreover, a shortage of skilled professionals and limited standardization in biomarker research methodologies can impact service quality and reproducibility, potentially affecting clinical outcomes. Variability in regulatory frameworks across regions may further hinder seamless outsourcing operations and market expansion.

Market Opportunities:

The market presents significant opportunities as demand for personalized therapies and precision diagnostics grows globally. Increasing R&D investments by pharmaceutical and biotech firms in developing targeted therapies are expected to boost outsourcing needs. Emerging markets in Asia-Pacific and Latin America offer untapped potential due to a rising patient base, growing healthcare infrastructure, and cost advantages. The integration of artificial intelligence (AI) and machine learning (ML) in biomarker analysis opens new avenues for innovation, enhancing discovery speed and accuracy. Strategic partnerships, mergers, and acquisitions among CROs and pharmaceutical companies can further accelerate market growth by expanding capabilities and service portfolios.

Key Questions Answered in the Report:

• What are the primary factors driving the global biomarker discovery outsourcing services market's growth?
• Which therapeutic areas and discovery phases are seeing the highest demand for outsourced services?
• How are technological advancements in genomics and AI influencing market dynamics?
• Who are the key players in the biomarker discovery outsourcing services market, and what strategies are they adopting?
• What are the emerging trends and future projections for the global biomarker discovery outsourcing services market?

Competitive Intelligence and Business Strategy:

Leading companies in the global biomarker discovery outsourcing services market, such as Laboratory Corporation of America Holdings, Celerion, Charles River Laboratories, and Thermo Fisher Scientific Inc., are focusing on expanding their biomarker service offerings and enhancing technological capabilities. Strategic collaborations with pharmaceutical firms and acquisitions of niche CROs are common strategies to gain a competitive edge. These companies are also investing in AI-powered analytics platforms and multi-omics approaches to improve biomarker identification and validation. By strengthening global laboratory networks and ensuring compliance with evolving regulatory standards, these players aim to meet growing industry demands efficiently.

Companies Covered in This Report:

• Laboratory Corporation of America Holdings
• Celerion
• Charles River Laboratories
• Eurofins Scientific
• GHO Capital
• ICON plc
• Evotec
• Parexel International (MA) Corporation
• Thermo Fisher Scientific Inc.
• Proteome Sciences

Market Segmentation:

By Biomarker Type:

• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Biomarkers

By Therapeutic Area:

• Oncology
• Cardiology
• Neurology
• Autoimmune Diseases
• Others

By Discovery Phase:

• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection

By End-use:

• Pharmaceutical Companies
• Biotechnology Companies
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Biomarker Discovery Outsourcing Services Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-economic Factors
  • 2.3.1. Impact of International Trade Policies on Analytical Instruments
  • 2.3.2. Economic Recovery and Increased Research Spending in Healthcare
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Biomarker Type Demand Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Biomarker Discovery Outsourcing Services Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Volume (Units) Projections
  • 4.1.2. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.3. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Biomarker Discovery Outsourcing Services Market Outlook: Biomarker Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Biomarker Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 4.3.3.1. Predictive Biomarkers
    • 4.3.3.2. Prognostic Biomarkers
    • 4.3.3.3. Safety Biomarkers
    • 4.3.3.4. Surrogate Biomarkers
  • 4.3.4. Market Attractiveness Analysis: Biomarker Type
• 4.4. Global Biomarker Discovery Outsourcing Services Market Outlook: Therapeutic Area
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
    • 4.4.3.1. Oncology
    • 4.4.3.2. Cardiology
    • 4.4.3.3. Neurology
    • 4.4.3.4. Autoimmune Diseases
    • 4.4.3.5. Others
  • 4.4.4. Market Attractiveness Analysis: Therapeutic Area
• 4.5. Global Biomarker Discovery Outsourcing Services Market Outlook: Discovery Phase
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Discovery Phase, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
    • 4.5.3.1. Biomarker Identification
    • 4.5.3.2. Biomarker Validation
    • 4.5.3.3. Biomarker Profiling
    • 4.5.3.4. Biomarker Panel Development
    • 4.5.3.5. Biomarker Selection
  • 4.5.4. Market Attractiveness Analysis: Discovery Phase
• 4.6. Global Biomarker Discovery Outsourcing Services Market Outlook: End Use
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 4.6.3.1. Pharmaceutical Companies
    • 4.6.3.2. Biotechnology Companies
    • 4.6.3.3. Others
  • 4.6.4. Market Attractiveness Analysis: End Use

5. Global Biomarker Discovery Outsourcing Services Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Biomarker Discovery Outsourcing Services Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Biomarker Type
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By Discovery Phase
  • 6.2.5. By End Use
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 6.4.1.
    • 6.4.1.1.
      • 6.4.1.1.1. Predictive Biomarkers
      • 6.4.1.1.2. Prognostic Biomarkers
      • 6.4.1.1.3. Safety Biomarkers
      • 6.4.1.1.4. Surrogate Biomarkers
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 6.5.1. Oncology
  • 6.5.2. Cardiology
  • 6.5.3. Neurology
  • 6.5.4. Autoimmune Diseases
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 6.6.1. Biomarker Identification
  • 6.6.2. Biomarker Validation
  • 6.6.3. Biomarker Profiling
  • 6.6.4. Biomarker Panel Development
  • 6.6.5. Biomarker Selection
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 6.7.1. Pharmaceutical Companies
  • 6.7.2. Biotechnology Companies
  • 6.7.3. Others
• 6.8. Market Attractiveness Analysis

7. Europe Biomarker Discovery Outsourcing Services Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Biomarker Type
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Discovery Phase
  • 7.2.5. By End Use
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 7.4.1.
    • 7.4.1.1.
      • 7.4.1.1.1. Predictive Biomarkers
      • 7.4.1.1.2. Prognostic Biomarkers
      • 7.4.1.1.3. Safety Biomarkers
      • 7.4.1.1.4. Surrogate Biomarkers
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 7.5.1. Oncology
  • 7.5.2. Cardiology
  • 7.5.3. Neurology
  • 7.5.4. Autoimmune Diseases
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 7.6.1. Biomarker Identification
  • 7.6.2. Biomarker Validation
  • 7.6.3. Biomarker Profiling
  • 7.6.4. Biomarker Panel Development
  • 7.6.5. Biomarker Selection
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 7.7.1. Pharmaceutical Companies
  • 7.7.2. Biotechnology Companies
  • 7.7.3. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Biomarker Discovery Outsourcing Services Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Biomarker Type
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Discovery Phase
  • 8.2.5. By End Use
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 8.4.1.
    • 8.4.1.1.
      • 8.4.1.1.1. Predictive Biomarkers
      • 8.4.1.1.2. Prognostic Biomarkers
      • 8.4.1.1.3. Safety Biomarkers
      • 8.4.1.1.4. Surrogate Biomarkers
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 8.5.1. Oncology
  • 8.5.2. Cardiology
  • 8.5.3. Neurology
  • 8.5.4. Autoimmune Diseases
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 8.6.1. Biomarker Identification
  • 8.6.2. Biomarker Validation
  • 8.6.3. Biomarker Profiling
  • 8.6.4. Biomarker Panel Development
  • 8.6.5. Biomarker Selection
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 8.7.1. Pharmaceutical Companies
  • 8.7.2. Biotechnology Companies
  • 8.7.3. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Biomarker Discovery Outsourcing Services Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Biomarker Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Discovery Phase
  • 9.2.5. By End Use
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 9.4.1.
    • 9.4.1.1.
      • 9.4.1.1.1. Predictive Biomarkers
      • 9.4.1.1.2. Prognostic Biomarkers
      • 9.4.1.1.3. Safety Biomarkers
      • 9.4.1.1.4. Surrogate Biomarkers
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 9.5.1. Oncology
  • 9.5.2. Cardiology
  • 9.5.3. Neurology
  • 9.5.4. Autoimmune Diseases
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 9.6.1. Biomarker Identification
  • 9.6.2. Biomarker Validation
  • 9.6.3. Biomarker Profiling
  • 9.6.4. Biomarker Panel Development
  • 9.6.5. Biomarker Selection
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 9.7.1. Pharmaceutical Companies
  • 9.7.2. Biotechnology Companies
  • 9.7.3. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Biomarker Discovery Outsourcing Services Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Biomarker Type
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Discovery Phase
  • 10.2.5. By End Use
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 10.4.1.
    • 10.4.1.1.
      • 10.4.1.1.1. Predictive Biomarkers
      • 10.4.1.1.2. Prognostic Biomarkers
      • 10.4.1.1.3. Safety Biomarkers
      • 10.4.1.1.4. Surrogate Biomarkers
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 10.5.1. Oncology
  • 10.5.2. Cardiology
  • 10.5.3. Neurology
  • 10.5.4. Autoimmune Diseases
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 10.6.1. Biomarker Identification
  • 10.6.2. Biomarker Validation
  • 10.6.3. Biomarker Profiling
  • 10.6.4. Biomarker Panel Development
  • 10.6.5. Biomarker Selection
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 10.7.1. Pharmaceutical Companies
  • 10.7.2. Biotechnology Companies
  • 10.7.3. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Biomarker Discovery Outsourcing Services Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Biomarker Type
  • 11.2.3. By Therapeutic Area
  • 11.2.4. By Discovery Phase
  • 11.2.5. By End Use
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 11.4.1.
    • 11.4.1.1.
      • 11.4.1.1.1. Predictive Biomarkers
      • 11.4.1.1.2. Prognostic Biomarkers
      • 11.4.1.1.3. Safety Biomarkers
      • 11.4.1.1.4. Surrogate Biomarkers
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 11.5.1. Oncology
  • 11.5.2. Cardiology
  • 11.5.3. Neurology
  • 11.5.4. Autoimmune Diseases
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 11.6.1. Biomarker Identification
  • 11.6.2. Biomarker Validation
  • 11.6.3. Biomarker Profiling
  • 11.6.4. Biomarker Panel Development
  • 11.6.5. Biomarker Selection
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 11.7.1. Pharmaceutical Companies
  • 11.7.2. Biotechnology Companies
  • 11.7.3. Others
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Laboratory Corporation of America Holdings
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Biomarker Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Celerion
  • 12.3.3. Charles River Laboratories
  • 12.3.4. Eurofins Scientific
  • 12.3.5. GHO Capital
  • 12.3.6. ICON plc
  • 12.3.7. Evotec
  • 12.3.8. Parexel International (MA) Corporation
  • 12.3.9. Thermo Fisher Scientific Inc.
  • 12.3.10. Proteome Sciences
  • 12.3.11. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료